TCRT (Alaunos Therapeutics, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by TCRT officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-11 | Holger Weis | CEO | A | — | — |
| 2026-07-27 | Holger Weis | CEO | A | — | — |
| 2026-07-27 | Michael Allen Jerman | Director | A | — | — |
| 2026-07-27 | Robert W Postma | Director | A | — | — |
| 2026-07-27 | Jaime Vieser | Director | A | — | — |
| 2026-07-02 | Holger Weis | Chief Executive Officer | A | — | — |
| 2026-06-17 | Holger Weis | Chief Executive Officer | A | — | — |
| 2026-05-27 | Holger Weis | Chief Executive Officer | A | — | — |
| 2026-05-01 | Michael Allen Jerman | Director | A | — | — |
| 2026-05-01 | Robert W Postma | Director | A | — | — |
| 2026-05-01 | Jaime Vieser | Director | A | — | — |
| 2026-01-15 | Michael Allen Jerman | Director | A | — | — |
| 2026-01-15 | Jaime Vieser | Director | A | — | — |
| 2026-01-15 | Robert W Postma | Director | A | — | — |
| 2025-11-26 | Robert W Postma | Director | A | — | — |
| 2025-11-26 | Michael Allen Jerman | Director | A | — | — |
| 2025-11-26 | Jaime Vieser | Director | A | — | — |
| 2025-08-20 | Holger Weis | Chief Executive Officer | A | — | — |
| 2025-08-20 | Ferdinand Groenewald | Vice President of Finance | A | — | — |
| 2025-07-17 | Michael Allen Jerman | Director | A | — | — |
| 2025-07-07 | Holger Weis | Chief Executive Officer | A | — | — |
| 2025-07-07 | Jaime Vieser | Director | A | — | — |
| 2025-07-07 | Robert W Postma | Director | A | — | — |
| 2025-06-26 | Jaime Vieser | Director | Buy | — | — |
| 2025-06-26 | Robert W Postma | Director | A | — | — |
| 2025-04-15 | Holger Weis | Director | A | — | — |
| 2025-04-15 | Robert W Postma | Director | A | — | — |
| 2025-04-15 | Jaime Vieser | Director | A | — | — |
| 2025-04-01 | Ferdinand Groenewald | VP, Finance | A | — | — |
| 2025-04-01 | Melinda Lackey | Legal & Administration | A | — | — |
| 2025-04-01 | Dale Curtis Hogue Jr. | See Remarks | A | — | — |
| 2025-01-03 | Jaime Vieser | Director | Sell | — | — |
| 2024-08-16 | Melinda Lackey | Legal & Administration | A | — | — |
| 2024-08-16 | Ferdinand Groenewald | VP, Finance | A | — | — |
| 2024-06-10 | Robert W Postma | Director | A | — | — |
| 2024-06-10 | Robert Hofmeister | Director | A | — | — |
| 2024-06-10 | Jaime Vieser | Director | A | — | — |
| 2024-06-10 | Holger Weis | Director | A | — | — |
| 2024-01-23 | Dale Curtis Hogue Jr. | Interim CEO | A | — | — |
| 2024-01-03 | Dale Curtis Hogue Jr. | Director | A | — | — |
| 2023-09-05 | Kevin S. Boyle Sr. | Chief Executive Officer | Sell | — | — |
| 2023-06-08 | Mary Thistle | Director | A | — | — |
| 2023-06-08 | Holger Weis | Director | A | — | — |
| 2023-06-08 | Robert W Postma | Director | A | — | — |
| 2023-06-08 | Jaime Vieser | Director | A | — | — |
| 2023-06-08 | James Huang | Director | A | — | — |
| 2023-06-08 | Robert Hofmeister | Director | A | — | — |
| 2023-04-19 | Robert Hofmeister | Director | A | — | — |
| 2023-03-17 | Melinda Lackey | See Remarks | A | — | — |
| 2023-03-17 | Abhishek K Srivastava | See Remarks | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 121,025 | — |
| — | Director | 49,742 | — |
| — | CEO | 25,490 | — |
| — | Director | 23,759 | — |
| — | Vice President of Finance | 10,775 | — |
| — | Chief Executive Officer | 5,322 | — |
| — | Director | 1,256 | — |
| — | Director | 300 | — |
| — | Director | 294 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the TCRT quote page; the site-wide leaderboard is on the insider transactions hub.